| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $7,285,493 ) |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK099511 | Novel Mechanisms of Exercise Training Effects on Glucose Homeostasis | 000 | 10 | NIH | 2/5/2024 | $743,850 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | K23DK137024 | Development of an intervention to target diabetes device use through an identity framework: ACCPTech (Adapt and Commit to CGM and Pump Technology) | 000 | 1 | NIH | 3/21/2024 | $190,284 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 000 | 2 | NIH | 3/11/2024 | $755,026 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161864 | Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes | 000 | 3 | NIH | 11/22/2023 | $774,662 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 000 | 3 | NIH | 11/13/2023 | $700,759 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 001 | 3 | NIH | 11/17/2023 | $77,861 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132469 | Transcriptional and epigenetic regulation of thermogenic adipocyte program | 000 | 3 | NIH | 4/2/2024 | $552,530 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129850 | Gut microbial fermentation products of muscle-derived lactate as mediators of exercise and metabolism | 000 | 3 | NIH | 3/22/2024 | $560,231 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK121967 | Interaction between genes, environment, the microbiome and metabolome in type 2 diabetes and metabolic syndrome | 000 | 5 | NIH | 2/21/2024 | $494,009 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK120445 | Functional Validation of Gene Modifications that Protect Beta Cells against Autoimmunity Identified by Genome-Wide CRISPR Cas9 Screening | 000 | 6 | NIH | 2/28/2024 | $380,250 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01EY026080 | Characterization of Retinoid-Binding Protein 3 (RBP3): A Protective Factor Against Diabetic Retinopathy Identified in People with Extreme Diabetes Duration | 000 | 7 | NIH | 1/16/2024 | $471,383 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK102898 | Fibroblast Growth Factor and Energy Metabolism | 000 | 9 | NIH | 4/5/2024 | $493,810 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK101043 | Exercise Regulation of Glucose Homeostasis | 000 | 26 | NIH | 2/21/2024 | $641,262 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis - Research Supplement to Promote Diversity in Health-Related Research | 000 | 7 | NIH | 2/13/2024 | $37,175 |
| | 2024 | 2024 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK031036 | Insulin Receptor Structure and Turnover | 000 | 43 | NIH | 2/23/2024 | $588,433 |
| | 2024 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161858 | Early myocardial remodeling and progressive kidney function decline in type 1 diabetes | 002 | 2 | NIH | 11/18/2023 | $78,761 |
| | 2024 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129479 | Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D | 000 | 3 | NIH | 11/6/2023 | $14,435 |
| | 2024 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | T32DK007260 | Training Grant in Diabetes and Metabolism | 000 | 47 | NIH | 1/18/2024 | $0 |
| | 2024 | 2022 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R21AG071436 | Identifying metabolic mechanisms that regulate appetite and foodintake | 000 | 2 | NIH | 1/16/2024 | $0 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R21HD101826 | Identification of Pathways Required for High Glucose-Induced Oxidative Stress Associated With Diabetic Embryopathy by CRISPR-Generated Mutation Screen | 000 | 2 | NIH | 11/8/2023 | -$1,063 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK048437 | 7/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center | 000 | 28 | NIH | 10/27/2023 | -$53,614 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK048437 | 7/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center | 000 | 28 | NIH | 10/27/2023 | -$53,614 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK048437 | 7/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center | 000 | 28 | NIH | 10/27/2023 | -$86,223 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK048437 | 7/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center | 000 | 28 | NIH | 10/27/2023 | -$11,794 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL067773 | Post-lysosomal cholesterol trafficking networks | 000 | 17 | NIH | 10/19/2023 | -$62,920 |
| | 2024 | 2021 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK064989 | Cellular Mechanisms that Promote or Prevent Lipotoxicity | 000 | 18 | NIH | 11/28/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $21,061,255 ) (Continued on the next page) |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK101043 | Exercise Regulation of Glucose Homeostasis | 000 | 25 | NIH | 2/1/2023 | $724,625 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | U01DK134996 | Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study) | 000 | 1 | NIH | 3/8/2023 | $166,817 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK120445 | Functional Validation of Gene Modifications that Protect Beta Cells against Autoimmunity Identified by Genome-Wide CRISPR Cas9 Screening | 001 | 5 | NIH | 2/17/2023 | $422,500 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129479 | Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D | 000 | 3 | NIH | 8/2/2023 | $687,285 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129479 | Improving Glycemia & Reducing Diabetes Distress in Adolescents & Young Adults with T1D | 001 | 3 | NIH | 8/30/2023 | $105,034 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK124258 | Mechanisms for Impaired Adaptation to Aerobic Exercise with Metabolic Disease | 000 | 4 | NIH | 8/2/2023 | $528,727 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R21MD017662 | A pilot clinical trial to assess feasibility, facilitators and barriers of continuous glucose monitoring in Asian Americans with type 2 diabetes | 001 | 2 | NIH | 8/25/2023 | $213,125 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK129850 | Gut microbial fermentation products of muscle-derived lactate as mediators of exercise and metabolism | 000 | 2 | NIH | 3/23/2023 | $634,993 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132469 | Transcriptional and epigenetic regulation of thermogenic adipocyte program | 000 | 2 | NIH | 3/24/2023 | $623,366 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK126799 | Development of Prognostic Algorithms to Identify Subjects at High Risk of ESKD in Type 2 Diabetes | 000 | 3 | NIH | 8/21/2023 | $725,018 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK133528 | Dissecting the thermogenic adipose niche | 000 | 2 | NIH | 8/30/2023 | $714,937 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK123459 | Understanding the role of the Complement Proteome in progressive Diabetic Kidney Disease | 000 | 4 | NIH | 3/15/2023 | $407,463 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK122808 | Role of brown fat-derived specialized pro-resolving lipid mediators in inflammation and metabolism | 000 | 4 | NIH | 1/30/2023 | $535,507 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R35GM122610 | Signaling mechanisms that detect stress and maintain homeostasis - Research Supplement to Promote Diversity in Health-Related Research | 001 | 7 | NIH | 8/16/2023 | $516,971 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01AG054215 | Homeostasis functions of SKN-1A/Nrf1 | 000 | 6 | NIH | 9/21/2023 | $599,011 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK082659 | Developmental genes, miRNAs and adipose tissue | 000 | 15 | NIH | 5/19/2023 | $700,075 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | P30DK036836 | Diabetes Research Center | 003 | 37 | NIH | 5/24/2023 | $1,703,578 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | T32DK007260 | Training Grant in Diabetes and Metabolism | 003 | 47 | NIH | 8/1/2023 | $740,757 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01HL161864 | Characterization of cardiovascular diseases (CVD) in people with long duration Type 1 diabetes | 001 | 2 | NIH | 5/12/2023 | $77,585 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK132535 | Elucidating and targeting beta-cell senescence and its SASP | 000 | 2 | NIH | 4/21/2023 | $426,979 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK128429 | Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin Resistance | 000 | 3 | NIH | 6/28/2023 | $589,410 |
| | 2023 | 2023 | JOSLIN DIABETES CENTER, INC. | 1 JOSLIN PL | BOSTON | MA | 02215-5306 | SUFFOLK | USA | R01DK131061 | Causal connections between axon guidance proteins and early progressive kidney function decline in diabetes | 000 | 2 | NIH | 2/14/2023 | $681,743 |
|
